KALARIS THERAPEUTICS, INC. Current Income Tax Expense (Benefit)
KALARIS THERAPEUTICS, INC. (KLRS) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-17
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2023-03-31 was $0.00.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2022-12-31 was -$465.00K, a 146.18% decline year-over-year.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2022-09-30 was $0.00.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for the quarter ending 2022-06-30 was $200.00K.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2025 was $0.00.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2024 was $0.00.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2023 was -$126.00K.
- KALARIS THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2022 was -$265.00K, a 126.32% decline from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month | Current Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2023-12-31 | -$126.00K 10-K · filed 2025-03-07 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | -$465.00K derived: sum of 2 quarters · filed 2024-03-15 | -$465.00K derived: sum of 3 quarters · filed 2024-03-15 | -$265.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-12-31 | -$465.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$465.00K derived: sum of 2 quarters · filed 2024-03-15 | -$265.00K derived: sum of 3 quarters · filed 2024-03-15 | -$265.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $200.00K derived: sum of 2 quarters · filed 2022-11-03 | $200.00K 10-Q · filed 2022-11-03 | $1.21M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $200.00K 10-Q · filed 2022-08-04 | $200.00K 10-Q · filed 2022-08-04 | $1.21M derived: sum of 3 quarters · filed 2023-05-04 | $1.21M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $1.01M derived: sum of 2 quarters · filed 2023-05-04 | $1.01M derived: sum of 3 quarters · filed 2023-05-04 | $1.01M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.01M derived: sum of 2 quarters · filed 2023-02-15 | $1.01M derived: sum of 3 quarters · filed 2023-02-15 | $1.01M 10-K · filed 2023-02-15 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-09-02 | $0.00 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |